Related Experiment Video
Updated: Apr 10, 2026
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Targeting IRAK1 in T-cell acute lymphoblastic leukemia
Charles Dussiau1, Amélie Trinquand1, Ludovic Lhermitte1
1Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de Recherche Médicale (INSERM) U1151 and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, Paris, France.
Interleukin receptor associated kinase 1 (IRAK1) is overexpressed in T-cell acute lymphoblastic leukemia (T-ALL). Genetic targeting of IRAK1 induces T-ALL cell death, but small molecule inhibitors show limited efficacy, suggesting a need for improved IRAK1 inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- T-cell acute lymphoblastic leukemia (T-ALL) has a 5-year survival rate of approximately 50%, necessitating novel therapeutic strategies.
- Interleukin receptor associated kinase 1 (IRAK1) is a kinase involved in Toll-like and Interleukin-1 Receptor signaling pathways.
Purpose of the Study:
- To investigate the role of IRAK1 in T-ALL pathogenesis.
- To evaluate IRAK1 as a potential therapeutic target in T-ALL.
Main Methods:
- Analysis of IRAK1 expression in T-ALL subtypes and normal thymic cells.
- Genetic knock-down of IRAK1 in T-ALL cell lines.
- Pharmacological inhibition of IRAK1 using a small molecule inhibitor (IRAK1/4-Inh).
Main Results:
- IRAK1 is overexpressed across all T-ALL subtypes compared to normal thymocytes.
- Genetic depletion of IRAK1 induces apoptosis, cell cycle arrest, and reduces proliferation in T-ALL cell lines.
- IRAK1 genetic knock-down reverses corticosteroid resistance in T-ALL cells.
- Pharmacological inhibition of IRAK1 partially replicates genetic knock-down effects.
Conclusions:
- IRAK1 is a functional kinase overexpressed in T-ALL, making it a promising therapeutic target.
- Next-generation IRAK1 inhibitors are required to fully exploit its therapeutic potential in T-ALL.
